DDCC 2,000%

SOYL 1,400%

STOCK BLOGS

Terra Tech Corp. (OTC: TRTC) has been making investors a boatload of profits!

TRTC has been on everyone’s radar as of late. Trading as low as $0.06 just last November TRTC has a 52 week high of $1.42 and is currently trading at $1.14. So, what is with this unbelievable increase in interest and PPS(Price Per Share) for TRTC? Up 1800% in just about five months there has to be something special that has caused this. Well this won’t be a surprise at all, but most of the interest that TRTC has undertaken is due to the explosion of interest in small cap Marijuana stocks. Also TRTC has had dozens of press releases in the last few months which tend to turn shareholders into advocates, and prospective shareholders into new shareholders. So what exactly does TRTC do business wise.

TRTC Through its wholly-owned subsidiary GrowOp Technology, Terra Tech Corp specializes in controlled environment agricultural technologies. The company integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. We work closely with expert horticulturists, engineers, and plant scientists to develop and manufacture advanced proprietary products for the fast-growing urban agricultural industry as well as individual hobbyists. Our products are utilized by Fortune 500 companies, small urban farmers, home enthusiasts, and traditional greenhouse growers. Our complete product line is available at specialty retailers throughout the United States, and via our website. Terra Tech Corp was incorporated in July 2008 in the State of Nevada; its subsidiary GrowOp Technology was founded March 2010, in Oakland, California.

Transfer Agent(s)

Furthermore TRTC does not actually have as large of a market cap as some of the other front running marijuana stocks out there. I have seen numerous other marijuana stocks with market caps well above $200 Million while TRTC is at $140 Million, which may mean it has some room to still grow. Keep an eye on TRTC for the next few weeks to see whether it will continue it’s positive run or run out of steam!

Tranzbyte Corp. OTC: ERBB is up 275% since we first reported on the company on February 7th. ERBB is another Marijuana stock that has encountered heavy liquidity, and price share appreciation due to the dramatic increase in interest in ERBB.

These Marijuana stocks cannot be taken lightly at this point. No promotion is the driving force behind these Marijuana stocks, but rather organic liquidity from investors, investor groups, traders, speculators, and institutional buyers.

The Tranzbyte Corporation ERBB has now become a driving force behind Altitude Organix, OneBode International, and the YO!21 Debit Card.

The company continues its plan to acquire, hold, or spin out successful divisions in what has been described in previous news releases as “dividend farming,” Subsidiary companies that qualify and decide to become public on their own can expect Tranzbyte’s continued support throughout the entire process.

Altitude Organix, a division of Tranzbyte Corporation, is currently developing and rolling out products within two sectors of the burgeoning medical and adult-use cannabis business. First, the company is developing ZaZZZ, what it believes will be the most advanced automated dispensary machine in the US.

Altitude Organix has also developed a proprietary debit card called YO!21 which will operate on the Tranzbyte-owned BancoLibre Network. The card is designed to be accepted at participating merchants nationwide and will operate the automated dispensary machines once they are rolled out in early 2014.

Tranzbyte also houses the company’s 10-year-old technology division which is actively engaged in the sale of its optical media enhancement products to potential customers in the US and Asia. Products in the Tranzbyte division include FLASHAlbum and FlixStix — technologies that enable distributors of optical media (CDs, DVDs, etc.) to consolidate the best features of each medium onto a single content-protected USB flash drive. Selected content for both FLASHAlbum and FlixStix will be available for purchase in the company’s automated ZaZZZ dispensary.

Service Providers

Overall many marijuana stocks are attempting to get involved with the actual distribution of the marijuana product through hardware products that are similar to vending machines that we have grown used to buying candy or potato chips from. ERBB has a product that most resembles the common vending machine, but there are others whoms products are very similar IMO like MDBX, EDXC, and others. It’s tough to tell who is going to come out on top of this specific aspect of the marijuana market. If you would like to know more about ERBB CLICK HERE TO SIGN UP FOR OUR FREE NEWSLETTER & RECEIVE A FREE FULL REPORT ON ERBB WITH PRICE TARGET!

Cellectar Biosciences (OTC: CLRB) But will the stock price finally go up?
Cellectar Biosciences (OTC: CLBR) is developing agents to detect, treat and monitor a broad spectrum of cancers. CLRB has many products that are currently in the trial phase, but understand that there are many other companies in the same sector and industry that have market caps in the Billions with little to no revenues as well. Right now CLRB has a very small market cap, and should on of it’s products pass the next couple trial phases this company is immediately valuated into the hundreds of millions if not billions. Approximately two years ago CLRB was trading around $2.00 per share which is over a 400% gain from current levels. Early this year CLRB formerly NVLT closed a private placement which secured the company $4,000,000. Now the convertible debentures, and warrants of this deal convert at $0.50 and $1.00 respectively. As I see it this means that CLRB will be trading at a much high price within the next couple years and more than likely much soon.

CLRB Utilizes a novel phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar’s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to “find, treat and follow” malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. A Phase II trial evaluating I-124-CLR1404 in glioblastoma is expected to be completed in 2014. Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors is anticipated in the first quarter of 2014. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit www.cellectar.com (source: pinksheets.com)

RECENT NEWS & HIGHLIGHTS

Mar 25, 2014

OTC Disclosure & News Service

MADISON, Wis., March 25, 2014 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the year ended December 31, 2013.

“Last year was the beginning of a significant transformation at Cellectar with changes implemented at every level, including our board of directors, executive leadership, strategic vision and, most recently, our company name,” commented Cellectar’s acting chief executive officer, Dr. Simon Pedder. “I am very pleased with the progress we made in just a few short months in not only refining our development strategy but, more importantly, in executing our clinical programs. Having prioritized the clinical development of our imaging agents, we are excited to have already initiated our first company-sponsored Phase II trial of I-124-CLR1404 in glioma and eagerly look forward to validating the proof-of-concept previously demonstrated in investigator-sponsored studies in this indication. Likewise, we plan to advance our optical imaging agent, CLR1502, into a Phase I trial later in the year. Both trials afford us the opportunity to meaningfully advance our pipeline in small, relatively short and cost-effective clinical trials intended to support regulatory approval in the US. I look forward to updating our shareholders on the upcoming milestones as appropriate and appreciate their support.”

Restructured Board of Directors, appointing Paul Berns as new independent director and reducing overall board membership from nine to five directors

2013 Financial Results and 2014 Guidance:

Cellectar reported a net loss attributable to common stockholders for the year ended December 31, 2013 of $10.8 million or ($0.19) per share compared to a net loss attributable to common stockholders of $9.3 million or ($0.23) per share for the year ended December 31, 2012.

Research and development expense for the year ended December 31, 2013 was approximately $6.9 million compared to approximately $5.1 million for 2012. This increase was primarily attributable to IND-enabling research activities related to CLR1502 and manufacturing activities related to I-124-CLR1404 and CLR1502. Cellectar anticipates full-year 2014 research and development expense to be between $8.0 and $9.0 million, reflecting costs associated with the company’s recently initiated Phase II imaging trial of I-124-CLR1404 in glioma patients and the anticipated initiation of a Phase I intraoperative optical imaging trial of CLR1502 in patients undergoing breast cancer surgery in the second half of 2014.

General and administrative expense for the year ended December 31, 2013 was approximately $4.4 million compared to approximately $3.6 million in 2012. The increase in general and administrative costs was primarily related to increased stock-based compensation charges and increased consulting and legal fees, some associated with governance and management changes. In 2014, Cellectar expects general and administrative expense to return to 2012 levels of between approximately $3.5 and $4.0 million.

As a result of management restructuring in 2013, Cellectar recorded approximately $1.1 million in restructuring expenses consisting primarily of stock-based compensation expense related to the modification of options for terminated employees.

For the year ended December 31, 2013, total operating expenses were $12.4 million. Cellectar’s cash and cash equivalents totaled $2.4 million as of December 31, 2013, as compared to $4.7 million on December 31, 2012.

On February 6, 2014, Cellectar completed the private placement of convertible debt and warrants that generated proceeds of $4.0 million. The proceeds of this offering will be used for further research and development of Cellectar’s pipeline. Cellectar anticipates that the cash and cash equivalents at year-end combined with net proceeds from its February offering will fund the company’s planned research and development programs through June 2014.

Operational Update:

I-124-CLR1404

Based on proof-of-concept demonstrated in multiple investigator-sponsored Phase I/II trials of I-124-CLR1404 in both primary and metastatic brain cancers, Cellectar initiated a company-sponsored Phase II imaging trial of I-124-CLR1404 in patients with newly diagnosed or recurrent glioblastoma during the first quarter of 2014. This trial, being conducted at multiple NCI-designated cancer centers in the U.S., will compare the efficacy of I-124-CLR1404 positron emission tomography (PET) imaging in detecting glioblastoma with standard of care MRI based on pathology confirmation in approximately 36 patients. Cellectar expects to complete this trial and announce results in the fourth quarter of 2014.

CLR1502

In 2013, Cellectar conducted extensive IND-enabling preclinical studies of CLR1502. Cellectar plans to submit an IND application to the U.S. Food and Drug Administration during the second quarter of 2014. The IND is expected to enable patient enrollment in a Phase I intraoperative optical imaging study of CLR1502 in approximately 20 patients undergoing lumpectomy commencing during the fourth quarter of 2014.

I-131-CLR1404

During the first quarter of 2014, Cellectar completed a Phase Ib dose escalation study of I-131-CLR1404 in patients with advanced solid tumors. In 2013, Cellectar reported that three of the six patients with advanced refractory solid tumors treated during the first three cohorts with I-131-CLR1404 had stable disease for up to four months, according to standard response evaluation criteria in solid tumors (RECIST 1.1), and confirmed by independent review. In May 2013, Cellectar reported that data from the third cohort indicated the onset of dose-limiting hematologic toxicities with I-131-CLR1404, triggering enrollment into a five-patient fourth cohort at a dose midway between the doses used in the second and third cohorts, as per trial protocol. Following completion of the fourth and final cohort of the Phase Ib trial in the first quarter of 2014, study investigators submitted the results of the Phase Ib trial of I-131-CLR1404 to the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting.

Conference Call and Webcast:

A conference call hosted by the Cellectar management team will be webcast live today at 5:00 pm EDT on the Cellectar Biosciences website. Interested investors may participate in the conference call by dialing 855-465-0185 (domestic) or 484-756-4315 (international). A replay will be available for one week following the call by dialing 800-585-8367 for domestic participants or 404-537-3406 for international participants and entering conference ID 16061248 when prompted. Participants may also access both the live and archived webcast of the conference call on Cellectar’s web site at www.cellectar.com.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar’s compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to “find, treat and follow” malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells. Data from a Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors is anticipated in the first quarter of 2014. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit www.cellectar.com

This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Moreover CLRB is a very solid and innovative company that has a bright future in front of it. The stock has traded very steady in it’s current range for quite sometime, building an extremely strong base. Keep an eye on CLRB it could start to breakout at anytime now.

While it’s contemporaries like MJNA, CBIS, HEMP etc. can’t quite seem to get their feet under them entirely. PHOT has been making huge moves.

Now why is PHOT so much hotter than the rest of the MMJ Stocks in the penny stock market? Maybe it is time to take a deeper look at these MMJ plays and figure out which ones are real and which ones are not so much.

PHOT first crossed our eyes when it was only $0.03. Since the company has went on to gain 2566%. In other words a $10,000 investment into PHOT at $0.03 would be worth over $250,000 currently, and this was just late last year.

If you are a shareholder or are thinking about becoming a shareholder of PHOT signup for our newsletter and receive a Free Report on PHOT.

NVLX has seen incredible volume over the last week, and many are saying this liquidity is strictly due to promotion of the stock.

From what I have seen NVLX has been being promoted by many email blasters, but at the same time these are not newsletters that bring much more than a couple hundred grand in liquidity normally while on Friday NVLX saw it’s stock trade 89,000,000 shares plus at an average price of $0.45. So, on Friday NVLX encountered liquidity of over $40,000,000.

Let me be frank the newsletters promoting NVLX did not bring in more than a million of this liquidity maybe two at a stretch!

NVLX as a stock is experiencing an overload of liquidity in my opinion because it is linked to the medical marijuana industry.

Signup for my Free Newsletter and I will send you a Free Full Report on NVLX or any other stock.

The Market Cap of NVLX is right in line with the market caps of MJNA , PHOT , FITX , and other penny stocks in the MMJ space.

Late last week a short from SeekingAlpha wrote a damning article on NVLX that may have caused the stock to take a dive on Friday. Since there has been much debate as to whether or not SeekingAlpha should allow such contributors that are disclosed shorts of stocks manipulate a stocks market like this short did to NVLX.

I am also of the opinion that companies like NVLX that have their companies security market manipulated by short sellers should sue them.

So, the big question where does NVLX go now. I think that it is feasible that the stock trades in the 30-40 cent range for sometime. There is also the possibility that the shorts continue to run havoc on NVLX and cause it to lose hundreds of millions more in market capitalization. Then there is the long view that the stock will rebound and surpass the beloved $1. For penny stocks hitting passing $1 is like scoring the hot cheerleader chick in high-school for us men.

Signup for my Free Newsletter and I will send you a Free Full Report on NVLX or any other stock.

BIEL closed out the week strong closing up 460% on over 1 BILLION shares traded!

We can see a ton of investors focusing on where this sub penny goes this upcoming week! There could be some profit taking but I have no doubt we can see another big run coming soon!

A lot of companies that offer pain management have been doing well but BEIL has a lot more to offer!

BIEL offers a DRUG FREE approach to pain relief and this could be the next big thing in health care!

A lot of companies are being sued due to horrible side effects that were not emphasized and this is causing a lot of problems for patients. Many people that are seeking pain relief are getting psychically and mentally addicted to pain killers. BIEL is being recognized in a big way because their method isn’t as harmful!

About BIEL:

BioElectronics Corporation develops, manufactures, and markets drugfree, topical pain medical devices. Its products comprise ActiPatch therapy for over-the-counter treatment of back pain and other musculoskeletal complaints; Allay menstrual cycle pain therapy; RecoveryRx for chronic and post-operative wound care; and HealFast therapy, a drug-free therapy for healing of muscle and tendon injuries, sores, and incision in horses, cats, and dogs. The company markets and sells its products under the ActiPatch, Allay, and RecoveryRx brand names through distributors primarily in Korea, Singapore, Malaysia, Canada, Columbia, Scandinavia, Saudi Arabia, the Balkans, Australia, China, and South America. BioElectronics Corporation was founded in 2000 and is based in Frederick, Maryland.

BIEL was recently nominated for most innovative new OTC product award! This is HUGE for BIEL, especially that it is only at the ground floor!

The ActiPatch® has been nominated for the “Best New OTC Packaging Design Award” and Smart Insole™ for “Most Innovative New OTC Product Award”.

The OTC Bulletin is firmly established as the most comprehensive and frequent source of news, views and analysis for pharmaceutical executives in the world’s leading consumer healthcare companies in over 45 countries.

The “Best New OTC Packaging Design” and “Most Innovative New OTC Product” awards are a few of the prestigious awards that make up the 2014 OTC Marketing Awards. Each award was judged by a panel of independent experts experienced and knowledgeable in the OTC market.

“We are excited to have again been nominated for the ‘Most Innovative New OTC Product’ award,” said Ben Fichter, Marketing Manager. “We believe our products will continue to be recognized and awarded as we Change the Way People Heal and Stop Pain.”

As you can see BIEL has been trading pretty flat for the past 3 months with small spikes here and there and recently, BAM it exploded!

This rise in PPS was highly anticipated and with the consistent news they are putting out we can see another run soon!

During 2013, extensive definition drilling and detailed mine planning to integrate the Hinge, 007 and Rice Lakes mines resulted in an increase in proven and probable mineral reserves to 2.7 million tons grading 5.24 grams per tonne containing 405,400 ounces of gold as of December 31, 2013. This is a 60% increase from the proven and probable mineral reserves as of December 31, 2012.

“I am very pleased with the progress made by our technical team over the past year. The increase in reserves has allowed us to complete five years of detailed mine planning, thereby providing improved operational flexibility. Our drilling in 2014 will be primarily from underground locations in closer proximity to known ore bodies. We expect to achieve a further increase in the mineral reserve as the year progresses through the conversion of our large inferred mineral resource,” said Ian Berzins, San Gold’s President, CEO and Chief Operating Officer.

Notes to Mineral Reserve and Resource Estimate Table

Mineral reserve and resource estimates are calculated in accordance with the CIM Definition Standards on Mineral Resources and Mineral Reserves adopted by CIM Council, 2010.

Tonnage and ounce estimates have been rounded to the nearest hundred.

Proven and probable mineral reserves are included in the measured and indicated mineral resources.

The mineral reserve estimate is based on a gold price of US$1,250 per ounce.

A cut-off grade of 3.65 g/tonne gold was used for estimating mineral reserves. A cut-off grade of between 2.74 and 3.43 g/tonne gold was used for estimating mineral resources.

Inferred mineral resources are not in the current mine plan and therefore do not have demonstrated economic viability.

The estimate of mineral resources was carried out under the supervision of Michael Michaud, Vice-President of Exploration. The estimate of mineral reserves was carried out under the supervision of Rolando Jeria, Chief Engineer. Mr. Michaud and Mr. Jeria are Qualified Persons as defined by NI 43-101, and have reviewed and approved this news release.

About SGRCF: San Gold Corporation engages in the exploration, development, and production of gold properties in Canada. It owns and operates the Rice Lake Mining Complex located northeast of Winnipeg, Manitoba, which include the Rice Lake, Hinge, and 007 mines. The companys Rice Lake Mining Complex includes 342 Mineral claims covering 41,973 hectares. It also has joint venture interests with other companies for the exploration of minerals in the provinces of Manitoba and Ontario. The company was formerly known as San Gold Resources Corporation and changed its name to San Gold Corporation in July 2005. San Gold Corporation was founded in 1997 and is headquartered in Winnipeg, Canada.

2 million ounces produced historically.

2.5 million ounces discovered since 2006.

Structural analysis revealing multiple new horizons within Company mining lease.

We saw a dip here at the close as profits were taken but still closed strong.

About EUENF: Eurasia Energy Limited, an exploration stage company, engages in the exploration of oil and gas. It focuses on negotiating an exploration, rehabilitation, development, and production sharing agreement for a 600 square kilometer oil and gas block in the Republic of Azerbaijan. The company was formerly known as Pacific Alliance Ventures Ltd. and changed its name to Eurasia Energy Limited in November 2005. Eurasia Energy Limited was incorporated in 2003 and is based in Peterhead, the United Kingdom.

With just under 35 million shares outstanding we can see a major move to the upside with the right push!

As you saw today EUENF only traded a little over 200k and we still saw a big jump!

In the past several months we have seen spike in volume followed by spike in PPS. In the past two months we saw it on a bigger scale. Is EUENF going to continue this pattern? Sign up to our FREE newsletter to receive the FULL report to start your due diligence!

You might want to read our full report before going further by simply signing up to our free newsletter.

Yet again we see another company getting involved in the cannabis sector and absolutely exploding! We believe a lot of these small cap companies that are trying their hand in the cannabis sector will do well in the short term and if they keep at it and are a solid company, for the long term as well.

You can sign up to our FREE newsletter and request a full report on PTOG to see if this is really a company you would like to own shares in.

PetroTech Oil and Gas, Inc. Set to Expand Into Legalized Cannabis Sector

BEDFORD, TX–(Marketwired – Feb 19, 2014) – PetroTech Oil and Gas Inc. (OTC Pink: PTOG) (the “Company” or Petrotech”) is pleased to announce today that they have set up a subsidiary company in Colorado, and Washington, to serve as the foundation for the company’s entry into the emerging market for medical and recently legalized recreational marijuana in the United States.

Through Legalizedpot.us, (LP.US Management Group Inc.) has been established to be the Management Company. This branch will specialize in managing the growers of legalized Marijuana and Hemp in the states where they are allowed to grow.

“This management group is the first of its kind, we have three growers in Colorado and Two in Washington, that will be our first clients,” said Steven Machat, the head of this new division.

About PTOG: Petrotech Oil and Gas, Inc. initiates, operates, and develops enhanced oil recovery opportunities within qualifying oil reservoirs in the United States. It offers work over and installation services; heavy equipment services; nitrogen, CO2, and gas mixture treatments; exhaust gas unit services; gas assisted gravity drainage services; and reservoir development plans. The company also operates as a construction and heavy equipment company that bids on various third party jobs for state and independent oil companies in the form of fee or joint ventures, including plugging of abandoned wells with state compliance agencies, as well as bids on road work for the state or independents. The company is based in Bedford, Texas.

Check out the one year chart on PTOG:

In the past year the stock has dropped significantly but as news comes out that PTOG is dabbling in the medical marijuana field anything is possible!

This is the hottest sector as of lately and we can see PTOG along with a lot of other companies that are getting involved in medical marijuana could do well!

Remember to sign up to our FREE newsletter to receive the full report on PTOG and any other stock you request!

We have been ranting and raving about how you should look into medical marijuana stocks and now there is even a BIGGER reason to!

US Banks are allowing medical marijuana companies to have bank accounts in the states!

This is HUGE news for PHOT and all of the other medical marijuana companies we have talked about. Not to mention this is going to be HUGE for some banks as well!

This business is going to continue to grow with more and more states legalizing the distribution of medical marijuana, now is the time to make the move, imo!

Check out the news here:

Pot Businesses Allowed to Open Accounts With U.S. Banks

The U.S. government took a step toward legitimizing the marijuana industry, allowing U.S. banks to offer accounts and other services to businesses in states where medical or recreational pot sales are legal.

The Treasury’s Financial Crimes Enforcement Network issued guidelines for banks intended to reduce the danger that sellers face in operating an all-cash business. The rules would also give law enforcement more information about marijuana business activity, the agency said yesterday in a statement.

“The idea that we can get checks written for stuff and use our credit cards, and paying taxes online would be fantastic,” said Elliott Klug, 36, co-founder of PinkHouse Blooms LLC, a chain of medical-marijuana dispensaries in Denver. He said he’s been using cash to pay $30,000 to $40,000 a month in state and local taxes and fees.

Marijuana remains an illegal substance under federal law. The guidelines were sought by pot businesses and the governors of Colorado and Washington state, whose voters in 2012 approved the first sales of marijuana for recreational use. Twenty states also permit medical marijuana.

About PHOT: Growlife, Inc., through its subsidiaries, manufactures and markets horticulture and lifestyle products in the United States and internationally. It offers LED lights for indoor growing; wireless monitoring and control equipment to operate grow room functions; and plant growing systems and accessories, including nutrients, media, timers, controls, and automated water accessories. The company also produces club and theatre shows, music tours, and festivals; owns and operates specialty hydroponics stores in Los Angeles and Cotai, California; and operates cannabis.org, an information portal for the medical marijuana industry. In addition, it sells hydroponic equipment online. The company was formerly known as SG Technology LLC and changed its name to Growlife, Inc. in April 2012. Growlife Inc. is based in Carson, California.

Make sure you sign up to our FREE newsletter to receive the full scoop!